Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Mallinckrodt
Colorcon
McKesson
Harvard Business School
Dow

Last Updated: August 19, 2022

Investigational Drug Information for Epelsiban


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the drug development status for Epelsiban?

Epelsiban is an investigational drug.

There have been 4 clinical trials for Epelsiban. The most recent clinical trial was a Phase 1 trial, which was initiated on July 1st 2016.

The most common disease conditions in clinical trials are Adenomyosis and [disabled in preview]. The leading clinical trial sponsors are GlaxoSmithKline and [disabled in preview].

There are nine US patents protecting this investigational drug and sixty-nine international patents.

Recent Clinical Trials for Epelsiban
TitleSponsorPhase
Placebo-controlled Proof of Concept Study of Epelsiban in Women With AdenomyosisGlaxoSmithKlinePhase 2
Dose Escalation Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Epelsiban Administered in Repeat Doses in Healthy Women VolunteersGlaxoSmithKlinePhase 1
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Epelsiban in Healthy Female VolunteersGlaxoSmithKlinePhase 1

See all Epelsiban clinical trials

Clinical Trial Summary for Epelsiban

Top disease conditions for Epelsiban
Top clinical trial sponsors for Epelsiban

See all Epelsiban clinical trials

US Patents for Epelsiban

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Epelsiban See Plans and Pricing Oxytocin receptor antagonist therapy in the luteal phase for implantation and pregnancy in women undergoing assisted reproductive technologies Ferring B.V. (Hoofddorp, NL) See Plans and Pricing
Epelsiban See Plans and Pricing Oxytocin receptor antagonist therapy in the luteal phase for implantation and pregnancy in women undergoing assisted reproductive technologies FERRING B.V. (Hoofddorp, NL) See Plans and Pricing
Epelsiban See Plans and Pricing Piperazinediones as oxytocin receptor antagonists Glaxo Group Limited (Greenford, Middlesex, GB) See Plans and Pricing
Epelsiban See Plans and Pricing Compounds Glaxo Group Limited (Greenford, Middlesex, GB) See Plans and Pricing
Epelsiban See Plans and Pricing Compounds Glaxo Group Limited (Greenford, Middlesex, GB) See Plans and Pricing
Epelsiban See Plans and Pricing Crystalline forms of (3R, 6R)-3-(2,3-dihydro-1H-inden-2-yl)-1-[(1R)-1-(2,6-dimethyl-3-pyridinyl)-2-- (4-morpholinyl)-2-oxoethyl]-6-[(1S)-1-methylpropyl]-2,5-piperazinedione Glaxo Group Limited (Brentford, Middlesex, GB) See Plans and Pricing
Epelsiban See Plans and Pricing Compounds Glaxo Group Limited (Brentford, Middlesex, GB) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Epelsiban

Drugname Country Document Number Estimated Expiration Related US Patent
Epelsiban Australia AU2015367900 2034-12-22 See Plans and Pricing
Epelsiban Brazil BR112017013521 2034-12-22 See Plans and Pricing
Epelsiban Canada CA2971846 2034-12-22 See Plans and Pricing
Epelsiban Chile CL2017001640 2034-12-22 See Plans and Pricing
Epelsiban China CN107249618 2034-12-22 See Plans and Pricing
Epelsiban China CN113940990 2034-12-22 See Plans and Pricing
Epelsiban Eurasian Patent Organization EA201791361 2034-12-22 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Mallinckrodt
Colorcon
McKesson
Harvard Business School
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.